

# Michael Baumann

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6865012/michael-baumann-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

313  
papers

12,016  
citations

59  
h-index

94  
g-index

371  
ext. papers

14,295  
ext. citations

4.2  
avg, IF

6.22  
L-index

#	Paper	IF	Citations
313	Strategien und Visionen des Nationalen Krebspräventionszentrums <b>2022</b> , 37, 38-41	0.2	
312	Das Nationale Krebspräventionszentrum. <i>Onkologe</i> , <b>2022</b> , 28, 62-68	0.1	1
311	Response to comment on "Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC".. <i>Radiotherapy and Oncology</i> , <b>2022</b> ,	5.3	
310	Randomisierte Studie zum Vergleich von Nebenwirkungen nach Protonen- versus Photonen-Strahlentherapie bei Patienten mit fortgeschrittenem nichtkleinzelligen Bronchialkarzinom <b>2022</b> , 37, 153-155	0.2	
309	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - hypothesis generation on a multicentre cohort of the DTKK-ROG.. <i>Radiotherapy and Oncology</i> , <b>2022</b> ,	5.3	2
308	The COVID-19 Pandemic and Cancer Patients in Germany: Impact on Treatment, Follow-Up Care and Psychological Burden.. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 788598	6	5
307	Final Results of the Prospective Biomarker Trial PETra: [C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1351-1360	12.9	5
306	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , <b>2021</b> ,	6.7	3
305	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
304	Das Deutsche Konsortium für Translationale Krebsforschung <b>2021</b> , 36, 465-473	0.2	
303	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 111, 1131-1139	4	2
302	Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy. <i>International Journal of Cancer</i> , <b>2021</b> , 150, 603	7.5	
301	Modelling of late side-effects following cranial proton beam therapy. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 157, 15-23	5.3	3
300	Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
299	Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 158, 262-267	5.3	0
298	Value of functional in-vivo endpoints in preclinical radiation research. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 158, 155-161	5.3	0
297	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. <i>Oncogene</i> , <b>2021</b> , 40, 4214-4228	8.2	11

296	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiation Oncology</i> , <b>2021</b> , 16, 141	4.2	2
295	Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 160, 69-77	5.3	3
294	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , <b>2021</b> , 21, 37-46	3.5	2
293	Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase III clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). <i>Strahlentherapie Und Onkologie</i> , <b>2021</b> , 197, 19-26	4.3	8
292	Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. <i>Strahlentherapie Und Onkologie</i> , <b>2021</b> , 197, 63-73	4.3	4
291	Radiotherapy enhances uptake and efficacy of Y-cetuximab: A preclinical trial. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 155, 285-292	5.3	6
290	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , <b>2021</b> , 26, 62-70	4.6	2
289	MRI-guided Radiation Therapy: An Emerging Paradigm in Adaptive Radiation Oncology. <i>Radiology</i> , <b>2021</b> , 298, 248-260	20.5	16
288	Dual role of ER stress in response to metabolic co-targeting and radiosensitivity in head and neck cancer cells. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 3021-3044	10.3	3
287	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 155, 204-211	5.3	1
286	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , <b>2021</b> , 11, 7844-7868	12.1	12
285	Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 3086-3096	7.5	0
284	Screening and Validation of Molecular Targeted Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 111, e63-e74	4	1
283	How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 1243-1269	4.4	16
282	In reply to the Letter to the Editor by Chen and Lui regarding "Radiotherapy enhances uptake and efficacy of Y-cetuximab: A preclinical trial" by A Dietrich et al. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 161, 261-262	5.3	
281	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2507-2543	7.9	1
280	Biomedical Research Goes Viral: Dangers and Opportunities. <i>Cell</i> , <b>2020</b> , 181, 1189-1193	56.2	4
279	What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1577-1585	7.9	8

278	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 149, 189-198	5.3	19
277	Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 143, 108-116	5.3	14
276	Radiotheranostics: a roadmap for future development. <i>Lancet Oncology</i> , <b>2020</b> , 21, e146-e156	21.7	59
275	Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 1427-1436	7.5	6
274	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 801-810	5.1	1
273	Preclinical In Vivo Evaluation of Novel Radiosensitizers by Local Tumor Control Experiments. <i>Cancer Drug Discovery and Development</i> , <b>2020</b> , 137-159	0.3	0
272	Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 143, 44-50	5.3	3
271	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 15625	4.9	11
270	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , <b>2020</b> , 15, 52-59	3.1	2
269	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1589-1615	7.9	15
268	Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 150, 262-267	5.3	3
267	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
266	Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 472-477	7.5	21
265	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , <b>2020</b> , 26, 665-671	50.5	201
264	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
263	Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual H2AX. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 139, 94-100	5.3	4
262	Cancer Core Europe: A translational research infrastructure for a European mission on cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 521-527	7.9	22
261	Cancer Prevention Europe. <i>Molecular Oncology</i> , <b>2019</b> , 13, 528-534	7.9	32

260	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3152-3163	12.9	29
259	Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 137, 24-31	5.3	5
258	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , <b>2019</b> , 16, 40-47	4.6	12
257	Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. <i>International Journal of Radiation Biology</i> , <b>2019</b> , 95, 900-911	2.9	13
256	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. <i>Acta Oncologica</i> , <b>2019</b> , 58, 916-925	3.2	7
255	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 135, 43-50	5.3	13
254	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. <i>Clinical and Translational Radiation Oncology</i> , <b>2019</b> , 15, 108-112	4.6	6
253	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 130, 164-171	5.3	16
252	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 130, 10-17	5.3	32
251	Onkologische Spitzenforschung [gelingt der Transfer in die Versorgung? <b>2019</b> , 34, 524-526	0.2	0
250	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1505-1516	12.9	35
249	Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. <i>British Journal of Radiology</i> , <b>2019</b> , 92, 20180539	3.4	9
248	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , <b>2019</b> , 75, 548-551	10.2	22
247	German Cancer Consortium (DKTK) - A national consortium for translational cancer research. <i>Molecular Oncology</i> , <b>2019</b> , 13, 535-542	7.9	12
246	Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy. <i>Research in Microbiology</i> , <b>2019</b> , 170, 74-79	4	24
245	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 130, 97-103	5.3	9
244	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , <b>2018</b> , 19, e240-e251	21.7	66
243	Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). <i>Cancer Medicine</i> , <b>2018</b> , 7, 1742-1749	4.8	19

242	Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 128, 121-127	5.3	31
241	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DTKK/ROG analysis. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 121-127	5.3	22
240	Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 126, 283-290	5.3	3
239	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 27-35	5.3	12
238	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1364-1374	12.9	32
237	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 126, 125-131	5.3	20
236	Union of light ion therapy centers in Europe (ULICE EC FP7) - Objectives and achievements of joint research activities. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 128, 83-100	5.3	5
235	Subjugation of TGF $\beta$ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6001-6014	12.9	44
234	In vivo imaging in the oral cavity by endoscopic optical coherence tomography. <i>Journal of Biomedical Optics</i> , <b>2018</b> , 23, 1-13	3.5	13
233	Stem cells in radiotherapy <b>2018</b> , 171-181		1
232	Research Facility for Radiobiological Studies at the University Proton Therapy Dresden. <i>International Journal of Particle Therapy</i> , <b>2018</b> , 5, 172-182	1.5	17
231	Prognostic value of SUR in patients with trimodality treatment of locally advanced esophageal carcinoma. <i>Journal of Nuclear Medicine</i> , <b>2018</b> ,	8.9	19
230	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , <b>2018</b> , 142, 1911-1925	7.5	32
229	Retrospective investigation of the prognostic value of the $\alpha$ integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy. <i>PLoS ONE</i> , <b>2018</b> , 13, e0209479	3.7	4
228	Heterogeneity of H2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	5
227	Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. <i>European Journal of Cancer</i> , <b>2018</b> , 103, 155-159	7.5	11
226	"Radiobiology of Proton Therapy": Results of an international expert workshop. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 128, 56-67	5.3	64
225	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. <i>Advanced Drug Delivery Reviews</i> , <b>2017</b> , 109, 63-73	18.5	179



224	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 122, 437-444	5.3	8
223	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , <b>2017</b> , 77, 2018-2028	10.1	59
222	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , <b>2017</b> , 141, 594-603	7.5	57
221	Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. <i>Oncotarget</i> , <b>2017</b> , 6, e1342909	7.2	16
220	Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1813-1822	8.8	9
219	The clinical target volume in lung, head-and-neck, and esophageal cancer: Lessons from pathological measurement and recurrence analysis. <i>Clinical and Translational Radiation Oncology</i> , <b>2017</b> , 3, 1-8	4.6	7
218	Clinical Implementation of Dual-energy CT for Proton Treatment Planning on Pseudo-monoenergetic CT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 97, 427-434	4	68
217	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , <b>2017</b> , 7, 13206	4.9	119
216	Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. <i>Radiation Oncology</i> , <b>2017</b> , 12, 190	4.2	19
215	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 533-540	5.3	90
214	Proton radiography for inline treatment planning and positioning verification of small animals. <i>Acta Oncologica</i> , <b>2017</b> , 56, 1399-1405	3.2	9
213	Ex vivo H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 386-394	5.3	12
212	Modeling in vivo relative biological effectiveness in particle therapy for clinically relevant endpoints. <i>Acta Oncologica</i> , <b>2017</b> , 56, 1392-1398	3.2	11
211	Tumor heterogeneity determined with a H2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 379-385	5.3	9
210	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , <b>2017</b> , 5, 28-36	4.6	14
209	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 496-503	5.3	15
208	Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , <b>2017</b> , 7, 36-42	4.6	9
207	Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. <i>Zeitschrift Fur Medizinische Physik</i> , <b>2017</b> , 27, 285-299	7.6	3

206	Bildung und Steuerung des Universitäts KrebsCentrum Dresden <b>2017</b> , 639-649		2
205	The Role of Cancer Stem Cells in Tumour Radioresponse <b>2016</b> , 43-74		
204	PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. <i>Trials</i> , <b>2016</b> , 17, 543	2.8	17
203	Protonentherapie bei Kindern mit Rhabdomyosarkom. <i>Info Onkologie</i> , <b>2016</b> , 19, 20-22		
202	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. <i>Recent Results in Cancer Research</i> , <b>2016</b> , 198, 107-22	1.5	10
201	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (AR095-06, SAKK10/94). <i>Strahlentherapie Und Onkologie</i> , <b>2016</b> , 192, 552-60	4.3	13
200	Kein Vorteil für das PFS bei Patienten mit lokal fortgeschrittenem NSCLC. <i>Info Onkologie</i> , <b>2016</b> , 19, 12-14		
199	An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. <i>EJNMMI Research</i> , <b>2016</b> , 6, 19	3.6	37
198	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DTKK-ROG. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2639-49	12.9	88
197	First clinical application of a prompt gamma based in vivo proton range verification system. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 118, 232-7	5.3	146
196	Toward Distributed Conduction of Large-Scale Studies in Radiation Therapy and Oncology: Open-Source System Integration Approach. <i>IEEE Journal of Biomedical and Health Informatics</i> , <b>2016</b> , 20, 1397-1403	7.2	11
195	Radiation oncology in the era of precision medicine. <i>Nature Reviews Cancer</i> , <b>2016</b> , 16, 234-49	31.3	438
194	An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. <i>Cancer Research</i> , <b>2016</b> , 76, 2637-51	10.1	48
193	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DTKK-ROG). <i>International Journal of Cancer</i> , <b>2016</b> , 138, 171-81	7.5	137
192	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 118, 350-8	5.3	40
191	Cancer: Education and Primary Prevention Starts in Childhood and Adolescence. <i>Journal of Cancer Therapy</i> , <b>2016</b> , 07, 851-856	0.2	
190	Precise image-guided irradiation of small animals: a flexible non-profit platform. <i>Physics in Medicine and Biology</i> , <b>2016</b> , 61, 3084-108	3.8	31
189	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DTKK-ROG). <i>Radiotherapy and Oncology</i> , <b>2016</b> , 121, 264-273	5.3	80



188	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , <b>2016</b> , 1, 19-26	4.6	16
187	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 121, 447-452	5.3	8
186	Electronic real-time assessment of patient-reported outcomes in routine care-first findings and experiences from the implementation in a comprehensive cancer center. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 3047-56	3.9	25
185	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3138-47	12.9	52
184	Fractionation Concepts. <i>Medical Radiology</i> , <b>2016</b> , 17-34	0.2	1
183	A Questionnaire Study to Assess the Value of the Vulnerable Elders Survey, G8, and Predictors of Toxicity as Screening Tools for Frailty and Toxicity in Geriatric Cancer Patients. <i>Oncology Research and Treatment</i> , <b>2016</b> , 39, 210-6	2.8	15
182	Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 91, 916-24	4	27
181	Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 115, 120-7	5.3	40
180	γH2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 116, 473-9	5.3	30
179	Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 429-37	8.8	36
178	Implementation of a software for REmote COMparison of PARTicle and photon treatment plans: ReCompare. <i>Zeitschrift Fur Medizinische Physik</i> , <b>2015</b> , 25, 287-94	7.6	8
177	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. <i>Acta Oncologica</i> , <b>2015</b> , 54, 1355-63	3.2	45
176	Global Task Force on Radiotherapy for Cancer Control. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1144-6	21.7	22
175	Expanding global access to radiotherapy. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1153-86	21.7	457
174	Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1150-6	8.9	45
173	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. <i>Acta Oncologica</i> , <b>2015</b> , 54, 1658-64	3.2	26
172	Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 116, 480-5	5.3	29
171	Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. <i>Radiation Oncology</i> , <b>2015</b> , 10, 172	4.2	26

170	Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 256	5.3	14
169	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 1165-1174	4	74
168	Aldehyde Dehydrogenase Is Regulated by $\beta$ Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. <i>Cancer Research</i> , <b>2015</b> , 75, 1482-94	10.1	157
167	Comparison study of in vivo dose response to laser-driven versus conventional electron beam. <i>Radiation and Environmental Biophysics</i> , <b>2015</b> , 54, 155-66	2	21
166	Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. <i>Oncotarget</i> , <b>2015</b> , 6, 34494-509	3.3	70
165	HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 255	3.2	1
164	Concept for individualized patient allocation: ReCompare--remote comparison of particle and photon treatment plans. <i>Radiation Oncology</i> , <b>2014</b> , 9, 59	4.2	16
163	Application of organ tolerance dose-constraints in clinical studies in radiation oncology. <i>Strahlentherapie Und Onkologie</i> , <b>2014</b> , 190, 621-4, 626-7	4.3	8
162	Be smart against cancer! A school-based program covering cancer-related risk behavior. <i>BMC Public Health</i> , <b>2014</b> , 14, 392	4.1	15
161	Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particles. <i>Radiation Oncology</i> , <b>2014</b> , 9, 57	4.2	14
160	Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 111, 81-7	5.3	32
159	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 110, 362-9	5.3	45
158	Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 159-66	4	18
157	Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasets. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 113, 303-9	5.3	62
156	Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro. <i>International Journal of Radiation Biology</i> , <b>2014</b> , 90, 678-86	2.9	7
155	EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. <i>Cancer Research</i> , <b>2014</b> , 74, 2825-34	10.1	50
154	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 112, 165-77	5.3	44
153	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , <b>2014</b> , 113, 217-23	5.3	100

152	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. <i>Pharmaceuticals</i> , <b>2014</b> , 7, 311-38	5.2	52
151	BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. <i>Radiation Oncology</i> , <b>2014</b> , 9, 207	4.2	39
150	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. <i>Radiation Oncology</i> , <b>2014</b> , 9, 261	4.2	9
149	Sun protection training based on a theater play for preschoolers: an effective method for imparting knowledge on sun protection?. <i>Journal of Cancer Education</i> , <b>2013</b> , 28, 435-8	1.8	7
148	Discovery of the cancer stem cell related determinants of radioresistance. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 108, 378-87	5.3	135
147	Reproducibility of target coverage in stereotactic spot scanning proton lung irradiation under high frequency jet ventilation. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 45-50	5.3	12
146	GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 299-304	5.3	43
145	Place of proton radiotherapy in future radiotherapy practice. <i>Seminars in Radiation Oncology</i> , <b>2013</b> , 23, 149-53	5.5	9
144	Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 147-54	5.3	60
143	Clinical perspectives of cancer stem cell research in radiation oncology. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 108, 388-96	5.3	74
142	Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 108, 422-8	5.3	13
141	Residual $\gamma$ H2AX foci predict local tumour control after radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 108, 434-9	5.3	32
140	Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond. <i>Journal of Radiation Research</i> , <b>2013</b> , 54 Suppl 1, i6-12	2.4	10
139	Inactivation of HNSCC cells by $^{90}\text{Y}$ -labeled cetuximab strictly depends on the number of induced DNA double-strand breaks. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 416-23	8.9	13
138	Cancer stem cells as a predictive factor in radiotherapy. <i>Seminars in Radiation Oncology</i> , <b>2012</b> , 22, 151-74	5.5	74
137	Monitoring PAI-1 and VEGF levels in 6 human squamous cell carcinoma xenografts during fractionated irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 84, e409-17	4	5
136	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 102, 444-9	5.3	21
135	Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 105, 21-8	5.3	229

134	Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2788-97	2.2	185
133	The impact of cell-cell contact, E-cadherin and EGF receptor on the cellular radiosensitivity of A431 cancer cells. <i>Radiation Research</i> , <b>2012</b> , 178, 224-33	3.1	7
132	Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study. <i>Lung Cancer</i> , <b>2012</b> , 78, 148-52	5.9	16
131	Individualization of cancer treatment from radiotherapy perspective. <i>Molecular Oncology</i> , <b>2012</b> , 6, 211-219	7.9	54
130	Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo. <i>Laboratory Investigation</i> , <b>2012</b> , 92, 1607-22	5.9	12
129	Radiobiological effectiveness of laser accelerated electrons in comparison to electron beams from a conventional linear accelerator. <i>Journal of Radiation Research</i> , <b>2012</b> , 53, 395-403	2.4	47
128	Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 1529-40	15.9	164
127	3D Semi-quantification of Nanoparticle Content in Tissue on Experimental and Commercial CT-Scanner. <i>Springer Proceedings in Physics</i> , <b>2012</b> , 111-115	0.2	
126	Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 99, 323-30	5.3	66
125	Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 101, 80-5	5.3	11
124	Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 100, 137-44	5.3	37
123	Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. <i>Strahlentherapie Und Onkologie</i> , <b>2011</b> , 187, 306-10	4.3	31
122	Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2011</b> , 38, 1203-11	8.8	99
121	Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 1205-13	4	53
120	Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 1181-8	4	31
119	EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. <i>Cancer Research</i> , <b>2011</b> , 71, 6261-9	10.1	95
118	Cancer stem cells: targets and potential biomarkers for radiotherapy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7224-9	12.9	79
117	CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5091-3	12.9	68

116	Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy. <i>Lung Cancer</i> , <b>2010</b> , 70, 280-5	5.9	17
115	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 94, 375-83	5.3	27
114	Glycolytic metabolism and tumour response to fractionated irradiation. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 94, 102-9	5.3	155
113	ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 338-45	5.3	42
112	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 36-9	5.3	13
111	Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 96, 116-22	5.3	70
110	Correlating quantitative MR measurements of standardized tumor lines with histological parameters and tumor control dose. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 96, 123-30	5.3	11
109	Effect of cetuximab and fractionated irradiation on tumour micro-environment. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 322-9	5.3	26
108	Transferring university knowledge to develop new technologies: the model of the "OncoRay &ndash; Joint Center for Radiation Research in Oncology". <i>International Journal of Healthcare Technology and Management</i> , <b>2010</b> , 11, 328	0.3	
107	Fractionation Concepts. <i>Medical Radiology</i> , <b>2010</b> , 13-26	0.2	
106	Cancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspective. <i>Seminars in Cancer Biology</i> , <b>2010</b> , 20, 116-24	12.7	84
105	PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 2516-27	15.9	80
104	Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. <i>International Journal of Radiation Biology</i> , <b>2009</b> , 85, 972-80	2.9	39
103	Serial FDG-PET on patients with head and neck cancer: implications for radiation therapy. <i>International Journal of Radiation Biology</i> , <b>2009</b> , 85, 796-804	2.9	31
102	Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation. <i>International Journal of Radiation Biology</i> , <b>2009</b> , 85, 772-80	2.9	17
101	Cancer stem cells and radiotherapy. <i>International Journal of Radiation Biology</i> , <b>2009</b> , 85, 391-402	2.9	65
100	Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining. <i>International Journal of Radiation Biology</i> , <b>2009</b> , 85, 1032-41	2.9	64
99	Impact of exogenous lactate on survival and radioresponse of carcinoma cells in vitro. <i>International Journal of Radiation Biology</i> , <b>2009</b> , 85, 989-1001	2.9	12

98	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. <i>International Journal of Radiation Biology</i> , <b>2009</b> , 85, 943-54	2.9	34
97	The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 90, 257-64	5.3	40
96	Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 92, 405-10	5.3	19
95	The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 92, 417-22	5.3	14
94	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 92, 353-61	5.3	34
93	Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 92, 460-5	5.3	9
92	Modified fractionation <b>2009</b> , 135-148		6
91	Combined radiotherapy and chemotherapy <b>2009</b> , 246-258		5
90	Tumor Biology Impact on Clinical Cure Rates. <i>Medical Radiology</i> , <b>2009</b> , 323-334	0.2	4
89	Molecular-targeted agents for enhancing tumour response <b>2009</b> , 287-300		3
88	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. <i>Journal of Pharmacy and Pharmacology</i> , <b>2008</b> , 60, 1019-28	4.8	25
87	Clonogens and cancer stem cells. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 990-990	31.3	6
86	Exploring the role of cancer stem cells in radioresistance. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 545-54	31.3	628
85	PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. <i>DNA Repair</i> , <b>2008</b> , 7, 1746-56	4.3	52
84	PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 86, 361-8	5.3	18
83	Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 88, 335-41	5.3	64
82	Inactivation of AP1 proteins by a nuclear serine protease precedes the onset of radiation-induced fibrosing alveolitis. <i>Radiation Research</i> , <b>2008</b> , 169, 531-42	3.1	7
81	Regionales Brustzentrum am Universitäts-Krebszentrum Dresden. <i>Breast Care</i> , <b>2008</b> , 3, 11-11	2.4	9



80	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. <i>Cancer and Metastasis Reviews</i> , <b>2008</b> , 27, 387-402	9.6	26
79	Effects of lovastatin alone or combined with irradiation on tumor cells in vitro and in vivo. <i>Strahlentherapie Und Onkologie</i> , <b>2008</b> , 184, 48-53	4.3	23
78	Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. <i>Strahlentherapie Und Onkologie</i> , <b>2007</b> , 183, 256-64	4.3	62
77	Experimental evaluation of functional imaging for radiotherapy. <i>Strahlentherapie Und Onkologie</i> , <b>2007</b> , 183 Spec No 2, 41-2	4.3	6
76	Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. <i>International Journal of Radiation Biology</i> , <b>2007</b> , 83, 793-802	2.9	26
75	Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation. <i>International Journal of Radiation Biology</i> , <b>2007</b> , 83, 827-36	2.9	5
74	Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. <i>Molecular Cancer Research</i> , <b>2007</b> , 5, 863-72	6.6	82
73	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 82, 96-104	5.3	37
72	EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 83, 238-48	5.3	157
71	EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumorigenic cells?. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 83, 316-25	5.3	46
70	Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 83, 304-10	5.3	126
69	Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 83, 311-5	5.3	52
68	Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. <i>Stem Cells and Development</i> , <b>2007</b> , 16, 439-46	4.4	69
67	Portal verification of high-energy electron beams using their photon contamination by film-cassette systems. <i>Strahlentherapie Und Onkologie</i> , <b>2006</b> , 182, 37-44	4.3	4
66	Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4119-26	12.9	177
65	Keynote comment: Radiotherapy in the age of molecular oncology. <i>Lancet Oncology, The</i> , <b>2006</b> , 7, 786-7	21.7	10
64	Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 78, 123-30	5.3	50
63	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 80, 112-22	5.3	64

62	Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 80, 178-84	5:3	35
61	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 81, 122-9	5:3	91
60	Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 81, 130-5	5:3	135
59	Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 74, 331-6	5:3	19
58	Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 74, 117-29	5:3	77
57	Towards equity in turbulent Europe ESTRO, European cooperation and the European Commission. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 75, 251-2	5:3	8
56	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 76, 206-12	5:3	36
55	Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 76, 143-50	5:3	123
54	Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 76, 162-7	5:3	81
53	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 76, 151-6	5:3	24
52	Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. <i>International Journal of Radiation Biology</i> , <b>2005</b> , 81, 751-8	2:9	31
51	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 61, 908-14	4	39
50	Ultrafractionation does not improve the results of radiotherapy in radioresistant murine DDL1 lymphoma. <i>Strahlentherapie Und Onkologie</i> , <b>2005</b> , 181, 540-4	4:3	15
49	Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 221-9	2:2	221
48	Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. <i>Cancer Research</i> , <b>2005</b> , 65, 5374-9	10:1	47
47	New anticancer agents: in vitro and in vivo evaluation. <i>In Vivo</i> , <b>2005</b> , 19, 1-7	2:3	36
46	TCP and NTCP: a basic introduction. <i>Rays</i> , <b>2005</b> , 30, 99-104		21
45	TCP and NTCP in preclinical and clinical research in Europe. <i>Rays</i> , <b>2005</b> , 30, 121-6		7

44	In vivo verification of electron beam energy by patient exit dose and optical density of portal films. <i>Strahlentherapie Und Onkologie</i> , <b>2004</b> , 180, 62-5	4.3	4
43	Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. <i>Strahlentherapie Und Onkologie</i> , <b>2004</b> , 180, 375-82	4.3	15
42	Impact of hypoxia and the metabolic microenvironment on radiotherapy of solid tumors. Introduction of a multi-institutional research project. <i>Strahlentherapie Und Onkologie</i> , <b>2004</b> , 180, 609-15	4.3	20
41	Molecular targeting in radiotherapy of lung cancer. <i>Lung Cancer</i> , <b>2004</b> , 45 Suppl 2, S187-97	5.9	22
40	Shaping the future: training of professionals for radiotherapy in Europe. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 70, 103-5	5.3	5
39	Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 72, 1-13	5.3	100
38	Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 72, 257-66	5.3	138
37	Physical and technical quality assurance in the CHARTWEL-Bronchus trial. <i>Strahlentherapie Und Onkologie</i> , <b>2003</b> , 179, 152-7	4.3	3
36	Ultrafractionation in human malignant glioma xenografts. <i>International Journal of Cancer</i> , <b>2003</b> , 107, 333; author reply 334	7.5	10
35	In regard to Solomon et al.: EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. <i>IJROBP</i> 2003;55:713-723. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 57, 300-1; author reply 301	4	5
34	Towards genetic prediction of radiation responses: ESTRO's GENEPI project. <i>Radiotherapy and Oncology</i> , <b>2003</b> , 69, 121-5	5.3	71
33	Selection of genetically distinct, rapidly proliferating clones does not contribute to repopulation during fractionated irradiation in FaDu squamous cell carcinoma. <i>Radiation Research</i> , <b>2003</b> , 160, 257-62	3.1	1
32	New targets for the modulation of radiation response--selective inhibition of the enzyme cyclooxygenase 2. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2003</b> , 3, 354-9		9
31	Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. <i>Anticancer Research</i> , <b>2003</b> , 23, 3869-76	2.3	34
30	Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. <i>Strahlentherapie Und Onkologie</i> , <b>2002</b> , 178, 411-21	4.3	20
29	Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2002</b> , 50, 197-204	3.4	58
28	2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. <i>Molecular Imaging and Biology</i> , <b>2002</b> , 4, 257-63	3.8	33
27	Metaanalyse klinischer Studien: Stein der Weisen oder des Anstoßs?. <i>Coloproctology</i> , <b>2001</b> , 23, 60-65	0.2	

26	The results of colorectal cancer treatment by p53 status: treatment-specific overview. <i>Diseases of the Colon and Rectum</i> , <b>2001</b> , 44, 322-33; discussion 333-4	3.1	47
25	The translational research chain: is it delivering the goods?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2001</b> , 49, 345-51	4	26
24	Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2001</b> , 51, 483-93	4	89
23	Rat model of lung fibrosis: comparison of functional, biochemical, and histopathological changes 4 months after single irradiation of the right hemithorax. <i>Toxicology</i> , <b>2001</b> , 161, 153-63	4.4	24
22	Wild-type sequence of TP53, intron 7. <i>Radiation Research</i> , <b>2001</b> , 155, 641	3.1	1
21	Radiobiological hypoxia, oxygen tension, interstitial fluid pressure and relative viable tumour area in two human squamous cell carcinomas in nude mice during fractionated radiotherapy. <i>Acta Oncologica</i> , <b>2001</b> , 40, 519-28	3.2	20
20	No evidence for a different magnitude of the time factor for continuously fractionated irradiation and protocols including gaps in two human squamous cell carcinoma in nude mice. <i>Radiotherapy and Oncology</i> , <b>2001</b> , 59, 187-94	5.3	9
19	Predictive factors in radiotherapy for non-small cell lung cancer: present status. <i>Lung Cancer</i> , <b>2001</b> , 31, 43-56	5.9	81
18	Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. <i>Lung Cancer</i> , <b>2001</b> , 33 Suppl 1, S35-45	5.9	22
17	Therapy of localized non-small cell lung cancer (take home messages). <i>Lung Cancer</i> , <b>2001</b> , 33 Suppl 1, S47-9	5.9	8
16	Hyperfractionated radiotherapy: tops or flops?. <i>Medical and Pediatric Oncology</i> , <b>1999</b> , 33, 399-402		5
15	Impact of overall treatment time on local control of slow growing human GL squamous cell carcinoma in nude mice treated by fractionated irradiation. <i>Radiotherapy and Oncology</i> , <b>1999</b> , 50, 107-115	5.3	16
14	Comparison of the response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules. <i>Strahlentherapie Und Onkologie</i> , <b>1998</b> , 174, 315-9	4.3	5
13	Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. <i>Radiotherapy and Oncology</i> , <b>1998</b> , 46, 127-30	5.3	34
12	Fractionation effect on radiation-induced growth retardation of tibia in rabbits and rats. <i>Acta Oncologica</i> , <b>1998</b> , 37, 151-8	3.2	5
11	Effect of irradiated volume on lung damage in pigs. <i>Radiotherapy and Oncology</i> , <b>1997</b> , 44, 35-40	5.3	32
10	Local Control as an End Point in Experimental Radiation Therapy of Human Tumor Xenografts. <i>Contributions To Oncology / Beitrage Zur Onkologie</i> , <b>1996</b> , 154-160		4
9	In vivo radiation sensitivity of glioblastoma multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1995</b> , 32, 99-104	4	60

8	Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. <i>Radiotherapy and Oncology</i> , <b>1994</b> , 32, 137-43	5.3	54
7	Present results of neutron therapy. The German experience. <i>Acta Oncologica</i> , <b>1994</b> , 33, 281-7	3.2	10
6	Impact of Tumor Stroma on Expression of the Tumor Bed Effect in R1H Rat Rhabdomyosarcoma. <i>Radiation Research</i> , <b>1994</b> , 140, 432	3.1	6
5	Response to Lindstrom and Fowler's "The influence of dose and time on local control of carcinoma of the larynx by radiation therapy". <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1992</b> , 22, 1163	4	
4	Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1992</b> , 23, 803-9	4	45
3	Metastases after fractionated radiation therapy of three murine tumor models. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1990</b> , 19, 367-70	4	13
2	Response of Human Squamous Cell Carcinoma Xenografts of Different Sizes to Irradiation: Relationship of Clonogenic Cells, Cellular Radiation Sensitivity in Vivo, and Tumor Rescuing Units. <i>Radiation Research</i> , <b>1990</b> , 123, 325	3.1	88
1	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy		1